• 목록
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional treatment and medications are not effective for a lot of patients suffering from depression. The individual approach to treatment could be the solution.

Cue is an intervention platform for digital devices that transforms passively acquired sensor data from smartphones into customized micro-interventions that improve mental health. We analyzed the most effective-fit personal ML models for each subject using Shapley values to discover their predictors of feature and reveal distinct features that are able to change mood as time passes.

Predictors of Mood

Depression is a major cause of mental illness across the world.1 Yet, only half of those with the condition receive treatment. In order to improve outcomes, clinicians need to be able to identify and treat patients with the highest chance of responding to specific treatments.

The treatment of depression can be personalized to help. Researchers at the University of Illinois Chicago are developing new methods for predicting which patients will benefit the most from specific treatments. They are using sensors on mobile phones as well as a voice assistant that incorporates artificial intelligence and other digital tools. With two grants totaling over $10 million, they will make use of these techniques to determine the biological and behavioral factors that determine the response to antidepressant medication and psychotherapy.

To date, the majority of research on predictors for depression treatment effectiveness has been focused on clinical and sociodemographic characteristics. These include demographics such as age, gender and education, and clinical characteristics like symptom severity and comorbidities as well as biological markers.

A few studies have utilized longitudinal data to predict mood in individuals. They have not taken into account the fact that mood can vary significantly between individuals. Therefore, it is important to develop methods which permit the analysis and measurement of individual differences in mood predictors, treatment effects, etc.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This allows the team to develop algorithms that can identify different patterns of behavior and emotions that differ between individuals.

The team also created a machine-learning algorithm that can model dynamic predictors for each person's depression mood. The algorithm blends the individual differences to produce a unique "digital genotype" for each participant.

The digital phenotype was associated with CAT DI scores, a psychometrically validated symptom severity scale. The correlation was low, however (Pearson r = 0,08; P-value adjusted by BH 3.55 x 10 03) and varied significantly between individuals.

Predictors of symptoms

Depression is one of the world's leading causes of disability1 yet it is often not properly diagnosed and treated. In addition, a lack of effective interventions and stigmatization associated with depression disorders hinder many people from seeking help.

To allow for individualized treatment in order to provide a more personalized treatment, identifying predictors of symptoms is important. However, current prediction methods depend on the clinical interview which is unreliable and only detects a tiny number of features associated with depression.2

Machine learning is used to blend continuous digital behavioral phenotypes captured by smartphone sensors and an online mental health tracker (the Computerized Adaptive Testing Depression Inventory the CAT-DI) with other predictors of severity of symptoms has the potential to improve the accuracy of diagnosis and the effectiveness of treatment for depression. Digital phenotypes are able to provide a wide range of distinct behaviors and activities, which are difficult to capture through interviews, and also allow for continuous and high-resolution measurements.

The study included University of California Los Angeles students who had mild to severe depression symptoms who were participating in the Screening and Treatment for Anxiety and Depression program29 that was developed as part of the UCLA Depression Grand Challenge. Participants were referred to online support or to clinical treatment according to the degree of their depression. Patients with a CAT DI score of 35 or 65 were given online support with the help of a coach. Those with a score 75 were sent to in-person clinics for psychotherapy.

At baseline, participants provided an array of questions regarding their personal demographics and psychosocial characteristics. The questions covered education, age, sex and gender, financial status, marital status as well as whether they divorced or not, their current suicidal thoughts, intentions or attempts, as well as how often they drank. The CAT-DI was used for assessing the severity of depression-related symptoms on a scale of zero to 100. CAT-DI assessments were conducted every other week for the participants who received online support and every week for those who received in-person support.

Predictors of Treatment Response

Personalized residential depression treatment uk treatment is currently a top research topic, and many studies aim at identifying predictors that will allow clinicians to identify the most effective medication for each person. Pharmacogenetics in particular is a method of identifying genetic variations that affect how the human body metabolizes drugs. This allows doctors to select medications that are likely to work best for each patient, while minimizing the time and effort involved in trials and errors, while avoid any adverse effects that could otherwise hinder advancement.

Another approach that is promising is to develop predictive models that incorporate information from clinical studies and neural imaging data. These models can be used to identify the variables that are most predictive of a particular outcome, such as whether a medication will improve mood or symptoms. These models can be used to determine a patient's response to treatment that is already in place which allows doctors to maximize the effectiveness of the current therapy.

A new generation of studies uses machine learning methods such as supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to combine the effects of multiple variables and increase predictive accuracy. These models have been proven to be effective in predicting treatment outcomes such as the response to antidepressants. These approaches are becoming more popular in psychiatry and will likely become the norm in the future treatment.

Research into depression's underlying mechanisms continues, as well as predictive models based on ML. Recent findings suggest that depression is related to the dysfunctions of specific neural networks. This theory suggests that a individualized treatment resistant depression Treatment for depression will be based upon targeted treatments that restore normal function to these circuits.

One method of doing this is by using internet-based programs that offer a more individualized and tailored experience for patients. One study found that a web-based program improved symptoms and led to a better quality of life for MDD patients. A controlled, randomized study of a personalized treatment for depression found that a significant number of participants experienced sustained improvement and fewer side negative effects.

Predictors of side effects

In the treatment of depression, the biggest challenge is predicting and determining which antidepressant medications will have very little or no side negative effects. Many patients have a trial-and error approach, with a variety of medications prescribed before finding one that is safe and effective. Pharmacogenetics provides a novel and exciting method to choose antidepressant drugs that are more effective and precise.

Several predictors may be used to determine which antidepressant is best to prescribe, including genetic variants, patient phenotypes (e.g. gender, sex or ethnicity) and co-morbidities. To determine the most reliable and accurate predictors of a specific treatment, random controlled trials with larger samples will be required. This is due to the fact that the identification of interaction effects or moderators could be more difficult in trials that only consider a single episode of treatment per participant instead of multiple sessions of treatment over time.

Additionally, the prediction of a patient's reaction to a specific medication is likely to require information on the symptom profile and comorbidities, in addition to the patient's prior subjective experiences with the effectiveness and tolerability of the medication. Presently, only a handful of easily measurable sociodemographic and clinical variables seem to be reliable in predicting response to MDD factors, including age, gender race/ethnicity, SES BMI, the presence of alexithymia, and the severity of depression symptoms.

The application of pharmacogenetics in treatment for depression treatment facility is in its early stages and there are many obstacles to overcome. First, it is essential to have a clear understanding and definition of the genetic mechanisms that underlie depression, and an accurate definition of a reliable predictor of treatment response. Ethics like privacy, and the responsible use genetic information should also be considered. The use of pharmacogenetics may be able to, over the long term reduce stigma associated with mental health treatments and improve the quality of treatment. Like any other psychiatric treatment it is crucial to take your time and carefully implement the plan. For now, it is recommended to provide patients with a variety of medications for depression that work and encourage patients to openly talk with their physicians.